Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Gross Profit: 2020-2025

Historic Gross Profit for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $10.0 million.

  • Janux Therapeutics' Gross Profit rose 2177.90% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 57.77%. This contributed to the annual value of $10.6 million for FY2024, which is 30.99% up from last year.
  • Janux Therapeutics' Gross Profit amounted to $10.0 million in Q3 2025, which was up 2,177.90% from $439,000 recorded in Q3 2024.
  • Janux Therapeutics' 5-year Gross Profit high stood at $10.0 million for Q3 2025, and its period low was $380,000 during Q1 2021.
  • Its 3-year average for Gross Profit is $3.6 million, with a median of $2.3 million in 2023.
  • As far as peak fluctuations go, Janux Therapeutics' Gross Profit plummeted by 82.56% in 2024, and later skyrocketed by 2,177.90% in 2025.
  • Janux Therapeutics' Gross Profit (Quarterly) stood at $1.6 million in 2021, then soared by 76.05% to $2.8 million in 2022, then dropped by 13.50% to $2.5 million in 2023, then plummeted by 82.56% to $439,000 in 2024, then soared by 2,177.90% to $10.0 million in 2025.
  • Its Gross Profit was $10.0 million in Q3 2025, compared to $439,000 in Q3 2024 and $8.9 million in Q2 2024.